Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Balcinrenone plus dapagliflozin versus dapagliflozin in chronic kidney disease with albuminuria
2023-509709-63-00Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD) and albuminuria comparing Balcinrenone + dapagliflozin with Dapagliflozin alone (2 arms). Primary endpoint: Relative change in UACR from baseline to Week 12. Started Jul 2024; status: completed.
02
Drugs
balcinrenonedapagliflozin
03
Conditions
chronic kidney disease (CKD)albuminuria
Beyond the preview
Go deeper on 2023-509709-63-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509709-63-00.